{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:19:25Z","timestamp":1791292765452,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":792,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report that ferroquine (FQ), an antimalarial ferrocenic analog of chloroquine, is a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines by affecting an early step of the viral life cycle. The antiviral activity of FQ on HCV entry was confirmed with pseudoparticles expressing HCV envelope glycoproteins E1 and E2 from six different genotypes. In addition to its effect on HCV entry, FQ also inhibited HCV RNA replication, albeit at a higher concentration. We also showed that FQ has no effect on viral assembly and virion secretion. Using a binding assay at 4\u00b0C, we showed that FQ does not prevent attachment of the virus to the cell surface. Furthermore, virus internalization was not affected by FQ, whereas the fusion process was impaired in the presence of FQ as shown in a cell-cell fusion assay. Finally, virus with resistance to FQ was selected by sequential passage in the presence of the drug, and resistance was shown to be conferred by a single mutation in E1 glycoprotein (S327A). By inhibiting cell-free virus transmission using a neutralizing antibody, we also showed that FQ inhibits HCV cell-to-cell spread between neighboring cells. Combinations of FQ with IFN, or an inhibitor of HCV NS3\/4A protease, also resulted in additive to synergistic activity. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: FQ is a novel, interesting anti-HCV molecule that could be used in combination with other direct-acting antivirals. (HEPATOLOGY 2013)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26273","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T16:05:14Z","timestamp":1359043514000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":52,"title":["The antimalarial ferroquine is an inhibitor of hepatitis C virus"],"prefix":"10.1097","volume":"58","author":[{"given":"Thibaut","family":"Vausselin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Calland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Belouzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Douam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Helle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Lavillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Duverlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"F\u00e9n\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Cocquerel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gu\u00e9rardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czeslaw","family":"Wychowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Biot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Dubuisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20241201","doi-asserted-by":"crossref","first-page":"107115","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus.","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"R2-14-20241201","first-page":"6877","article-title":"New directacting antivirals combination for the treatment of chronic hepatitis C.","volume":"31","author":"Asselah","year":"2011","journal-title":"Liver Int"},{"key":"R3-14-20241201","doi-asserted-by":"crossref","first-page":"14671475","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM1): a randomised, doubleblind, placebocontrolled, doseescalation trial.","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"R4-14-20241201","doi-asserted-by":"crossref","first-page":"216224","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1.","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-14-20241201","doi-asserted-by":"crossref","first-page":"69196928","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low and verylowdensity hepatitis C virus RNAcontaining particles.","volume":"76","author":"Andre","year":"2002","journal-title":"J Virol"},{"key":"R7-14-20241201","first-page":"933945","article-title":"Hepatitis C virus entry into the hepatocyte.","volume":"6","author":"Belouzard","year":"2011","journal-title":"Cent Eur J Biol"},{"key":"R8-14-20241201","doi-asserted-by":"crossref","first-page":"69646972","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrinmediated endocytosis.","volume":"80","author":"Blanchard","year":"2006","journal-title":"J Virol"},{"key":"R9-14-20241201","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cellcell transmission in hepatoma cells in the presence of neutralizing antibodies.","volume":"47","author":"Timpe","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R10-14-20241201","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus celltocell transmission in hepatoma cells.","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J Gen Virol"},{"key":"R11-14-20241201","doi-asserted-by":"crossref","first-page":"37153718","DOI":"10.1021\/jm970401y","article-title":"Synthesis and antimalarial activity in vitro and in vivo of a new ferrocenechloroquine analogue.","volume":"40","author":"Biot","year":"1997","journal-title":"J Med Chem"},{"key":"R12-14-20241201","doi-asserted-by":"crossref","first-page":"910912","DOI":"10.1039\/C1CC16211J","article-title":"In situ nanochemical imaging of labelfree drugs: a case study of antimalarials in Plasmodium falciparuminfected erythrocytes.","volume":"48","author":"Dubar","year":"2012","journal-title":"Chem Commun (Camb)"},{"key":"R13-14-20241201","doi-asserted-by":"crossref","first-page":"207214","DOI":"10.1051\/parasite\/2011183207","article-title":"The antimalarial ferroquine: from bench to clinic.","volume":"18","author":"Biot","year":"2011","journal-title":"Parasite"},{"key":"R14-14-20241201","doi-asserted-by":"crossref","first-page":"28452849","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"key":"R15-14-20241201","first-page":"38583863","article-title":"Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res"},{"key":"R16-14-20241201","doi-asserted-by":"crossref","first-page":"61476160","DOI":"10.1128\/jvi.68.10.6147-6160.1994","article-title":"Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.","volume":"68","author":"Dubuisson","year":"1994","journal-title":"J Virol"},{"key":"R17-14-20241201","doi-asserted-by":"crossref","first-page":"62356244","DOI":"10.1128\/JVI.73.8.6235-6244.1999","article-title":"Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.","volume":"73","author":"Flint","year":"1999","journal-title":"J Virol"},{"key":"R18-14-20241201","doi-asserted-by":"crossref","first-page":"11951198","DOI":"10.1099\/0022-1317-72-5-1195","article-title":"Characterization of monoclonal antibodies to bovine viral diarrhoea virus: evidence of a neutralizing activity against the gp 48 in the presence of a goat antimouse immunoglobulin serum.","volume":"72","author":"Boulanger","year":"1991","journal-title":"J Gen Virol"},{"key":"R19-14-20241201","first-page":"791796","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"R20-14-20241201","doi-asserted-by":"crossref","first-page":"773787","DOI":"10.1128\/JVI.01190-09","article-title":"Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.","volume":"84","author":"Goueslain","year":"2010","journal-title":"J Virol"},{"key":"R21-14-20241201","doi-asserted-by":"crossref","first-page":"24952503","DOI":"10.1099\/vir.0.82872-0","article-title":"Robust production of infectious viral particles in Huh7 cells by introducing mutations in hepatitis C virus structural proteins.","volume":"88","author":"Delgrange","year":"2007","journal-title":"J Gen Virol"},{"key":"R22-14-20241201","doi-asserted-by":"crossref","first-page":"e1866","DOI":"10.1371\/journal.pone.0001866","article-title":"The CD81 partner EWI2wint inhibits hepatitis C virus entry.","volume":"3","author":"RochaPerugini","year":"2008","journal-title":"PLoS One"},{"key":"R23-14-20241201","doi-asserted-by":"crossref","first-page":"29943002","DOI":"10.1128\/JVI.78.6.2994-3002.2004","article-title":"Characterization of functional hepatitis C virus envelope glycoproteins.","volume":"78","author":"Op De Beeck","year":"2004","journal-title":"J Virol"},{"key":"R24-14-20241201","doi-asserted-by":"crossref","first-page":"74087413","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-14-20241201","doi-asserted-by":"crossref","first-page":"596605","DOI":"10.1128\/JVI.01592-10","article-title":"Neutralizing antibodyresistant hepatitis C virus celltocell transmission.","volume":"85","author":"Brimacombe","year":"2011","journal-title":"J Virol"},{"key":"R26-14-20241201","doi-asserted-by":"crossref","first-page":"51595167","DOI":"10.1128\/AAC.00633-11","article-title":"Griffithsin has antiviral activity against hepatitis C virus.","volume":"55","author":"Meuleman","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-14-20241201","doi-asserted-by":"crossref","first-page":"28322841","DOI":"10.1128\/JVI.80.6.2832-2841.2006","article-title":"Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.","volume":"80","author":"Rouille","year":"2006","journal-title":"J Virol"},{"key":"R28-14-20241201","doi-asserted-by":"crossref","first-page":"1251512528","DOI":"10.1128\/JVI.01393-10","article-title":"Identification of basic amino acids at the Nterminal end of the core protein that are crucial for hepatitis C virus infectivity.","volume":"84","author":"Alsaleh","year":"2010","journal-title":"J Virol"},{"key":"R29-14-20241201","doi-asserted-by":"crossref","first-page":"227234","DOI":"10.1016\/j.jcv.2004.03.009","article-title":"TaqMan amplification system with an internal positive control for HCV RNA quantitation.","volume":"31","author":"Castelain","year":"2004","journal-title":"J Clin Virol"},{"key":"R30-14-20241201","doi-asserted-by":"crossref","first-page":"9981007","DOI":"10.1002\/hep.25501","article-title":"Role of lowdensity lipoprotein receptor in the hepatitis C virus life cycle.","volume":"55","author":"Albecka","year":"2012","journal-title":"HEPATOLOGY"},{"key":"R31-14-20241201","doi-asserted-by":"crossref","first-page":"18751884","DOI":"10.1053\/j.gastro.2010.02.004","article-title":"Glucocorticosteroids increase cell entry by hepatitis C virus.","volume":"138","author":"Ciesek","year":"2010","journal-title":"Gastroenterology"},{"key":"R32-14-20241201","doi-asserted-by":"crossref","first-page":"87528765","DOI":"10.1128\/JVI.02642-06","article-title":"Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus.","volume":"81","author":"Lavillette","year":"2007","journal-title":"J Virol"},{"key":"R33-14-20241201","doi-asserted-by":"crossref","first-page":"79948004","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"R35-14-20241201","doi-asserted-by":"crossref","first-page":"i25i35","DOI":"10.1136\/gutjnl-2012-302048","article-title":"New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.","volume":"61","author":"Ploss","year":"2012","journal-title":"Gut"},{"key":"R36-14-20241201","doi-asserted-by":"crossref","first-page":"185193","DOI":"10.1021\/mp0500061","article-title":"Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity.","volume":"2","author":"Biot","year":"2005","journal-title":"Mol Pharm"},{"key":"R37-14-20241201","first-page":"47224730","article-title":"Foamy virus envelope glycoproteinmediated entry involves a pHdependent fusion process.","volume":"77","author":"PicardMaureau","year":"2003","journal-title":"J Virol"},{"key":"R38-14-20241201","doi-asserted-by":"crossref","first-page":"857864","DOI":"10.1128\/jvi.52.3.857-864.1984","article-title":"Effects of lysosomotropic weak bases on infection of BHK21 cells by Sindbis virus.","volume":"52","author":"Cassell","year":"1984","journal-title":"J Virol"},{"key":"R39-14-20241201","doi-asserted-by":"crossref","first-page":"284293","DOI":"10.1128\/jvi.43.1.284-293.1982","article-title":"Infectious cell entry mechanism of influenza virus.","volume":"43","author":"Yoshimura","year":"1982","journal-title":"J Virol"},{"key":"R40-14-20241201","doi-asserted-by":"crossref","first-page":"275287","DOI":"10.1021\/cb100322v","article-title":"The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance.","volume":"6","author":"Dubar","year":"2011","journal-title":"ACS Chem Biol"},{"key":"R41-14-20241201","doi-asserted-by":"crossref","first-page":"710716","DOI":"10.1021\/mp800007x","article-title":"Investigation of the redox behavior of ferroquine, a new antimalarial.","volume":"5","author":"Chavain","year":"2008","journal-title":"Mol Pharm"},{"key":"R42-14-20241201","doi-asserted-by":"crossref","first-page":"1015910168","DOI":"10.1128\/JVI.01180-10","article-title":"Characterization of the envelope glycoproteins associated with infectious hepatitis C virus.","volume":"84","author":"Vieyres","year":"2010","journal-title":"J Virol"},{"key":"R43-14-20241201","doi-asserted-by":"crossref","first-page":"195203","DOI":"10.1007\/s00535-009-0132-9","article-title":"Inhibition of hepatitis C virus replication by chloroquine targeting virusassociated autophagy.","volume":"45","author":"Mizui","year":"2010","journal-title":"J Gastroenterol"},{"key":"R44-14-20241201","doi-asserted-by":"crossref","first-page":"13421357","DOI":"10.3390\/v3081342","article-title":"Impact of the autophagy machinery on hepatitis C virus infection.","volume":"3","author":"Dreux","year":"2011","journal-title":"Viruses"},{"key":"R45-14-20241201","doi-asserted-by":"crossref","first-page":"31653173","DOI":"10.1128\/AAC.05359-11","article-title":"Pharmacokinetics of ferroquine, a novel 4aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.","volume":"56","author":"Supan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-14-20241201","doi-asserted-by":"crossref","first-page":"973978","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation.","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26273","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201307000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:15:13Z","timestamp":1733062513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201307000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26273","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}